Part I
Articles by LPBI Group’s Team Member
Adipocyte Derived Stroma Cells: Their Usage in Regenerative Medicine and Reprogramming into Pancreatic Beta-Like Cells
Curator: Evelina Cohn, PhD
Fat Cells Reprogrammed to Make Insulin
Curator: Larry H. Bernstein, MD, FCAP
Part II
Diabetes: All Drugs in Development
Curator: Stephen J Williams, PhD
| Table 1. Drugs in Development1–3 | |||
| Generic/Code Name | Manufacturer | Indication | Phase |
| DPP-4 Inhibitors | |||
| Alogliptin/SYR-322 | Takeda | Type 2 diabetes | NDA submitted |
| AMG 222/ALS2- 0426 | Amgen/Servier | Type 2 diabetes | 2 |
| Dutogliptin/PHX1149 | Phenomix/Forest Laboratories | Type 2 diabetes | 3 |
| KRP-204/N-5984 | Kyorin | Type 2 diabetes | 2 |
| KRP-104 | Kyorin/ActivX Biosciences | Type 2 diabetes | 2 |
| Linagliptin/BI-1356 | Boehringer Ingelheim | Type 2 diabetes | 3 |
| Melogliptin/GRC 8200 | Glenmark Pharmaceuticals | Type 2 diabetes | 2 |
| MP-513 | Mitsubishi Tanabe Pharma | Type 2 diabetes | 2 |
| PF 734200 | Pfizer | Type 2 diabetes | 2 |
| R1579 | Roche/Chugai | Type 2 diabetes | 2 |
| Saxagliptin/BMS-477118 | Bristol-Myers Squibb/AstraZeneca | Type 2 diabetes | NDA submitted |
| SYR 472 | Takeda | Type 2 diabetes | 2 |
| TA-6666 | Mitsubishi Tanabe | Type 2 diabetes | 2 |
| Vildagliptin | Novartis | Type 2 diabetes | NDA submitted |
| GLP-1 Analogs | |||
| Albiglutide/GSK716155 | GSK | Type 2 diabetes | 2 |
| AVE0010/ZP-10 | Sanofi-Aventis | Type 2 diabetes | 3 |
| CJC-1134-PC/PC-DAC: Exendin-4 | ConjuChem | Type 2 diabetes | 2 |
| Exenatide LAR | Amylin/Alkermes/Lilly | Type 2 diabetes | 3 |
| Liraglutide/NN2211 | Novo Nordisk | Type 2 diabetes | NDA submitted |
| LY 2189265 | Lilly | Type 2 diabetes | 3 |
| NN9535 | Novo Nordisk | Type 2 diabetes | 2 |
| Taspoglutide/R1583/BIM-51077 | Roche/Ipsen | Type 2 diabetes | 3 |
| Biguanides | |||
| Metformin gum/buccal | Generex/Fertin Pharma | Type 2 diabetes | 2 |
| Thiazolidinediones/PPAR-γ Agonists | |||
| Balaglitazone/DRF-2593 | Dr. Reddy’s Laboratories/Rheoscience | Type 2 diabetes | 3 |
| Mitoglitazone/MDSC 0160 | Metabolic Solutions Development | Type 2 diabetes | 2 |
| Netoglitazone/MCC-55 | Mitsubishi Tanabe/Perlegen | Type 2 diabetes | 2 |
| Rivoglitazone/CS-011 | Daiichi-Sankyo | Type 2 diabetes | 3 |
| Other PPAR Agonists | |||
| Aleglitazar/R1439 | Roche | Type 2 diabetes | 2 |
| Indeglitazar | Pexxikon/Wyeth | Type 2 diabetes | 2 |
| INT 131/AMG131 | Amgen/InteKrin Therapeutics | Type 2 diabetes | 2 |
| MBX 2044 | Metabolex/Ortho-McNeil | Type 2 diabetes | 2 |
| Metaglidasen/MBX 102/JNJ-39659100 | Metabolex/Ortho-McNeil | Type 2 diabetes | 2 |
| ONO-5129 | Ono | Type 2 diabetes | 2 |
| PLX204/PPM-204 | Plexxikon/Wyeth | Type 2 diabetes | 2 |
| Selective Sodium Glucose Cotransporter Inhibitors | |||
| ASP1941 | Astellas | Type 2 diabetes | 2 |
| AVE2268 | Sanofi-Aventis | Type 2 diabetes | 2 |
| BI 10773 | Boehringer Ingelheim | Type 2 diabetes | 2 |
| Dapagliflozin/BMS512148 | AstraZeneca/Bristol-Myers Squibb | Type 2 diabetes | 3 |
| KGT-1681 | GSK/Kissei | Type 2 diabetes | 2 |
| Remogliflozin/189075 | GSK/Kissei | Type 2 diabetes | 2 |
| TA-7284 | Mitsubishi Tanabe/Ortho McNeil | Type 2 diabetes | 2 |
| YM543 | Astellas | Type 2 diabetes | 2 |
| Glinides | |||
| Mitiglinide | Elixir Pharmaceuticals | Type 2 diabetes | 3 |
| Insulins | |||
| Inhaled Technosphere insulin | Mannkind | Type 1 and type 2 diabetes | 3 |
| Insulin intranasal | Bentley | Type 1 and type 2 diabetes | 2 |
| Insulin intranasal | MDRNA | Type 2 diabetes | 2 |
| Oral HDV insulin | Diasome | Type 2 diabetes | 2 |
| Oral insulin spray | Generex | Type 1 and type 2 diabetes | 3 |
| NN1250 insulin analog for injection |
Novo Nordisk | Type 1 and type 2 diabetes | 2 |
| NN5401 insulin analog for injection |
Novo Nordisk | Type 1 and type 2 diabetes | 2 |
| Rapid-acting insulin for injection | Biodel | Type 1 and type 2 diabetes | 3 |
| Recombinant human hyaluroindase (rHuPH20)/insulin co-formulation for injection | Halozyme Therapeutics | Type 1 diabetes | 2 |
| Other Drugs in Development | |||
| Generic/Code Name | Manufacturer | Mechanism | Indication |
| AJD101 | Daiichi Sankyo | Activates insulin signaling pathway | Type 2 diabetes |
| AKP- 020 | Akesis | Vanadium compound | Type 2 diabetes |
| AMG-108 | Amgen | Interleukin-1 inhibitor | Type 2 diabetes |
| AZD6370 | AstraZeneca | Glucokinase activator | Type 2 diabetes |
| Bromocriptine | VeroScience | Dopamine D2 receptor agonist |
Type 2 diabetes |
| Canakinumab/ACZ885 | Novartis | Anti-interleukin-1 beta antibody | Type 2 diabetes |
| Colestimide | Mitsubishi-Tanabe | Unknown | Type 2 diabetes |
| Bezafibrate + diflunisal/ CRx-401 | CombinatoRx | Unknown | Type 2 diabetes |
| DIO-902/2S,4R ketoconazole | DiObex | Cortisol synthesis inhibitor | Type 2 diabetes |
| DM-71/bethanechol and N-acetyl cysteine | Diamedica | Unknown | Type 2 diabetes |
| DM-83/combination of two generic compounds | Diamedica | Unknown | Type 2 diabetes |
| E1 INT | Transition Therapeutics | Islet regeneration factor | Type 1 and type 2 diabetes |
| Eprodisate/NC-503 | Bellus Health | Serum amyloid A protein inhibitor | ? |
| Ex vivo cultured adult human mesenchymal stem cells | Osiris | Mesenchymal stem cell therapy |
Type 1 diabetes |
| HE3286 | Hollis-Eden | Insulin sensitizer (NF-kappaB pathway/TLR4 receptor) | Type 2 diabetes |
| INCB 13739 | Incyte | 11-beta hydroxysteroid dehydrogenase inhibitor | Type 2 diabetes |
| INCB 19602 | Incyte | GPR109A receptor agonist / HM74a agonist | Type 2 diabetes |
| INGAP peptide | Kinexum | Islet neogenesis associated protein | Type 1 and type 2 diabetes |
| ISIS 113715 | Isis | PTP1B | Type 2 diabetes |
| MB 07803 | Metabasis/Daiichi Sankyo |
Fructose-1,6-bisphosphatase inhibitor | Type 2 diabetes |
| MK 0893 | Merck | Unknown | Type 2 diabetes |
| MK 0941 | Merck | Unknown | Type 2 diabetes |
| Otelixizumab/TRX4 | GSK, Tolerx | Anti-CD3 MAb | Type 1 diabetes |
| rhGAD65/recombinant human glutamic acid decarboxylase | Diamyd Therapeutics | Vaccine/induces immunmotolerization | Type 1 diabetes |
| Succinobucol/AGI 1067 | AtheroGenics | Antioxidant/vascular cell adhesion molecule-1 | Type 2 diabetes |
| Tagatose | Spherix | Attenuates intestinal glucose absorption | Type 2 diabetes |
| Teplizumab/MGA031/ hOKT3gamma1(Ala-Ala) | Lilly/MacroGenics | Anti-CD3 MAb | Type 1 diabetes |
| TT-223 | Lilly/Transition Therapeutics | Gastrin analog | Type 1 and type 2 diabetes |
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Abhisar Anand
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Daniel Menzin
Dror Nir
dsmolyar
Ethan Coomber
evelinacohn
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
komal23ingle
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
Dr. Pati
pkandala
Rosalind Codrington, PhD
ritusaxena
Rick Mandahl
satwik Sunnam
sjwilliamspa
Srinivas Sriram
stuartlpbi
Dr. Sudipta Saha
tildabarliya
vaishnavee24
zraviv06
zs22